As of November 6, 2026, Ionis Pharmaceuticals Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on June 8, 2026, naming 1 appointment. The latest filing names Ludwig N. Hantson, appointed (Form 8-K, June 8, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Ionis Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Ionis Pharmaceuticals Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-06-08. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Ionis Pharmaceuticals Inc files it.
Also on the record for Ionis Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| May 15, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 3.7% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Capital World Investors | 12.8% of the class | 5%+ stakes | Source |
| April 30, 2026 | Stake report, Schedule 13G, by Vanguard Capital Management | 5.05% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 5.6% of the class | 5%+ stakes | Source |
| January 7, 2026 | Stake report, Schedule 13G/A, by Capital World Investors | 11.1% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 8.3% of the class | 5%+ stakes | Source |
| August 12, 2025 | Stake report, Schedule 13G/A, by Wellington Management Group LLP | 4.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Ionis Pharmaceuticals Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Ionis Pharmaceuticals Inc and the records around it.
Ionis Pharmaceuticals Inc elsewhere on the record
Companies that share a holder
- Capital World Investors also filed stake reports on 125 other companies: New Fortress Energy Inc. (Oct 2026), Aura Minerals Inc. (Oct 2026), Skyworks Solutions, Inc. (Oct 2026)
- T. Rowe Price Investment Management, Inc. also filed stake reports on 167 other companies: CABALETTA BIO INC (Nov 2026), MADISON SQUARE GARDEN SPORTS CORP (Nov 2026), MSG RANGERS CORP (Nov 2026)
- Wellington Management Group LLP also filed stake reports on 240 other companies: Hub Group, Inc. (Oct 2026), Latham Group, Inc. (Oct 2026), Redwood Trust, Inc. (Oct 2026)
Watch Ionis Pharmaceuticals Inc
Get an email when Ionis Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ionis Pharmaceuticals Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Ionis Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ionis Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-06-08 | In | 2026-06-04 | 8-K, 2026-06-08 |
New leaders reset buying decisions — get the Full Report on Ionis Pharmaceuticals Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Ionis Pharmaceuticals Inc, with the record behind each one.
Find candidates like senior executive at Ionis Pharmaceuticals IncEvery change, in the filing's words
Appointed: Ludwig N. Hantson, effective 2026-06-04
(d) Appointment of Ludwig N. Hantson to the Board of Directors On June 4, 2026, the Board of Directors (" Board ") of Ionis Pharmaceuticals, Inc. (the " Company ") appointed Ludwig N. Hantson as a member of the Company's Board effective June 4, 2026, immediately following the Company's 2026 Annual Meeting of Stockholders.
- Dr. Hantson has more than 30 years of leadership experience at biopharmaceutical and medical device companies.
- He served as chief executive officer and board member of Alexion from 2017-2021, prior to its acquisition by AstraZeneca.
- Before joining Alexion, Dr. Hantson served as president of Baxter Bioscience, where he led the spin-off of Baxalta, serving as chief executive officer and board member.
- Earlier in his career, he held senior leadership roles at Novartis across North America and Europe, including chief executive officer of North America, and spent 13 years at Johnson & Johnson in roles of increasing responsibility.
- In addition to serving as a director at Alexion and Baxalta, Dr. Hantson served as a director at Hologic, a medical device innovator.
- He holds a master's degree in physical education and a Ph.D. in motor rehabilitation & physical therapy from the University of Louvain in Belgium.
- In addition, Dr. Hantson will enter into the Company's standard form of indemnity agreement.
Tools for this story
Each opens in a new tab, filled in for Ionis Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.